Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsMechanisms of drug resistance: daptomycin resistanceEfficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsTreatment of Gram-positive infections in critically ill patientsStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibioticsHigh-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin SynergyDaptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream InfectionsHigh-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure.Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureusCurrent and prospective treatments for multidrug-resistant gram-positive infections.Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposureβ-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.[Multiresistant gram-negative bacteria. A bacterial challenge of the twenty-first century].Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.Failure of daptomycin to kill Staphylococcus aureus: impact of bacterial membrane fatty acid composition.Safety of high-dose daptomycin in patients with severe renal impairment.Detection of Biofilm-associated Implant Pathogens in Cardiac Device Infections: High Sensitivity of Sonication Fluid Culture Even in the Presence of Antimicrobials.
P2860
Q26752922-1BCD01FD-11EE-43D9-B793-C30B9CE54B4FQ26779944-6BAD68DF-9909-4907-902D-25F7A1CF96C2Q27000445-06F5C7FB-CCA4-41A0-8031-8D3A3E420E10Q27015976-1284C502-ADD7-464B-BFB1-41F7334B79B0Q34478074-FCB4A5F7-7977-4FF1-BBAC-0E9913362695Q35169018-D372637A-D55D-417E-9602-36A25DD2E524Q35385568-8C28FA8F-99F9-41BD-9BB9-6B29C1B27FFDQ35848781-52656618-1A0D-453F-81E1-0FF5158C1001Q36439093-BF9DB7C0-C942-4EF8-AA9D-699999D76C91Q37287739-060FB303-2F4E-4952-A53F-31C31AEF9B58Q37291084-175F167D-A4A6-411B-AE38-1222DEC60BFFQ37538754-BCE2A117-F809-4BAE-ABAB-0690EE92BCB6Q37544579-C4715ACD-9D38-4E10-8593-2B1E1D4A5F63Q37588890-2AAC69E0-F9D2-41C3-9046-5105C4C7A4E8Q38123255-0564DCB0-359E-48E4-8ADF-B9D4F3032FD3Q38232494-AB3CB3D5-BE0C-4854-96A5-1619D8C5E1F1Q40083539-4858FE4C-1E23-4827-A9DF-C4F3F78F3051Q40845477-81CC7F21-7B4D-4E55-A7A4-FD40C4B345C0Q41825567-589DE0DE-F908-4F44-821F-C8E0855B89A9Q42099202-6A7E558D-CDA7-4C66-8770-EA25B36EE2DFQ43430110-62E5DF26-A528-4BD9-8E7E-7E124C131FE5Q47634145-01F157AB-738F-4E2E-863D-D3EA4428CA18Q53686599-7CF5396B-12A6-44A0-BA45-1F14262A3CF1Q54120294-495EF509-245D-4F23-A23D-DE846E1DD0CDQ55231337-A67741AF-2198-4CB6-9E39-68EB9E510FA1
P2860
Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Multicenter evaluation of the ...... to moderate renal impairment.
@ast
Multicenter evaluation of the ...... to moderate renal impairment.
@en
type
label
Multicenter evaluation of the ...... to moderate renal impairment.
@ast
Multicenter evaluation of the ...... to moderate renal impairment.
@en
prefLabel
Multicenter evaluation of the ...... to moderate renal impairment.
@ast
Multicenter evaluation of the ...... to moderate renal impairment.
@en
P2093
P2860
P356
P1476
Multicenter evaluation of the ...... to moderate renal impairment.
@en
P2093
Anjay Rastogi
George Sakoulas
Holly L Hoffman-Roberts
Kenneth C Lamp
Maria Amodio-Groton
Min J Yoon
Mohamad Rashid
Pamela A Moise
Suzanne Schweitzer
P2860
P304
P356
10.1128/AAC.02192-12
P407
P577
2012-12-17T00:00:00Z